It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Agenus Inc (AGEN) Com Stk USD0.01

Sell:$3.23 Buy:$3.31 Change: $0.03 (0.93%)
Market closed |  Prices as at close on 17 May 2021 | Switch to live prices |
Sell:$3.23
Buy:$3.31
Change: $0.03 (0.93%)
Market closed |  Prices as at close on 17 May 2021 | Switch to live prices |
Sell:$3.23
Buy:$3.31
Change: $0.03 (0.93%)
Market closed |  Prices as at close on 17 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Contact details

Address:
3 Forbes Rd
LEXINGTON
02421-7305
United States
Telephone:
+1 (781) 6744400
Website:
agenusbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AGEN
ISIN:
US00847G7051
Market cap:
$718.48 million
Shares in issue:
222.44 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Garo Armen
    Chairman of the Board, Chief Executive Officer, Co-Founder
  • Jennifer Buell
    President, Chief Operating Officer
  • Christine Klaskin
    Chief Accounting Officer, Vice President - Finance
  • Donald Vidic
    Vice President - Head of Commercial
  • Adam Krauss
    Chief Legal Officer, General Counsel
  • Andy Hurley
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.